Ian has been covering a broad range of topics across the Japanese and Asian pharma industry, including corporate, M&A, R&D, pricing and policy developments, since 1988. After a stint as Tokyo-based Japan and Asia editor for Scrip, in 2014 he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet). In his current position, he directs regional coverage for Scrip and Pink Sheet and manages a multinational, on-the-ground team. Ian is a recipient of multiple internal and external awards and a regular participant in APAC conferences, webinars and events, and produces regular podcasts. He has spent the majority of his life in Asia, having grown up in Hong Kong, and enjoys cycling and music.
Latest from Ian Haydock
In this week's episode: many blockbusters to fade this year: semaglutide’s India reckoning; multinationals look beyond simple China licensing; Almirall eyes China dermatology assets; EU urged to restore biopharma competitiveness.
In this week's episode: Roche faces giredestrant Phase III setback; founders exit BioNTech; Ipsen to withdraw Tazverik; tough times for Bayer; and another boost for UCB’s Bimzelx.
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
In this week's episode: Hudson’s legacy at Sanofi; the realities behind Trump’s US pharma investment push; Bayer’s precision medicine approach and growth; clinical trials to look out for this year; and Scrip Asks on AI and operational excellence.
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.